宜明昂科-B(01541.HK)預計9月5日上市 引入藥明生物等多家基石
格隆匯8月24日丨宜明昂科-B(01541.HK)發佈公吿，公司擬全球發售1714.72萬股股份，其中中國香港發售股份171.48萬股，國際發售股份1543.24萬股，另有15%超額配股權；2023年8月24日至8月29日招股；發售價將為每股發售股份18.60港元，每手買賣單位200股，入場費約3757港元；摩根士丹利及中金公司為聯席保薦人；預期股份將於2023年9月5日於聯交所主板掛牌上市。
公司於2015年6月在中國成立，是一家臨牀階段的生物技術公司，致力於開發腫瘤免疫療法。公司已開發核心產品IMM01(處於臨牀階段的創新CD47靶向分子)。公司的管線包括以基於先天免疫的全面資產組合為特色及靶向CD47及其他新型免疫檢查點的14款候選藥物(包括IMM01)，其中有八個正在進行的臨牀項目。
公司已訂立基石投資協議，據此，基石投資者已同意按發售價認購以總金額2970萬美元(約2.32億港元)可購買的發售股份數目。基石投資者將按發售價18.60港元認購的發售股份總數將為1248.52萬股發售股份。基石投資者包括Harvest、WuXi Biologics Healthcare Venture(由藥明生物(02269.HK)全資擁有及最終控制)、榮昌生物香港有限公司(榮昌生物(09995.HK/688331.SH)的全資附屬公司)、以及昆翎醫藥發展有限公司。
按發售價每股H股18.60港元計算，假設超額配股權未獲行使，公司的全球發售所得款項淨額總額將約為2.33億港元。公司目前擬將全球發售的有關所得款項淨額約40.0%用於公司核心產品IMM01(SIRPα-Fc融合蛋白)正在進行及計劃開展的臨牀試驗、籌備註冊申請以及計劃的商業化上市；約28.0%將用於公司核心產品IMM0306(CD47×CD20)、 IMM2902(CD47×HER2)及IMM2520(CD47×PD-L1)正在進行及計劃開展的臨牀試驗、籌備註冊申請以及計劃的商業化上市；約10.0%將用於IMM47(CD24單克隆抗體)計劃開展的臨牀試驗；約5.0%將用於IMM2510 (VEGF×PD-L1)及IMM27M(CTLA4 ADCC增強型單克隆抗體)正在進行的臨牀試驗；約7.0%將用於建設公司於上海張江科學城的新生產設施；約5.0%將用於公司多個臨牀前及發現階段資產(包括但不限於IMM4701、IMM51、IMM38、IMM2547、IMM50 及IMM62)的 持續臨牀前研發以及CMC以支持臨牀試驗，包括各種資產的關鍵試驗；及約5.0%將用於營運資金及一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
